Posaconazole: a new broad-spectrum antifungal agent

Bibliography

• MARR KA, CARTER RA, CRIPPA F, WALD A, COREY L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. (2002) 34(7):909-917.
   PubMed Web of Science ®Google Scholar
• MCNEIL MM, NASH SL, HAJJEH RA et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. (2001) 33(5):641-647.
   PubMed Web of Science ®Google Scholar
• MAERTENS J: Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur. J. Haematol. (2007) 78(4):275-282.
   PubMed Web of Science ®Google Scholar
• MARTY FM, COSIMI LA, BADEN LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. (2004) 350(9):950-952.
   PubMed Web of Science ®Google Scholar
• GROLL AH, PISCITELLI SC, WALSH TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. (1998) 44:343-500.
   PubMedGoogle Scholar
• GROLL AH, WALSH TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti Infect. Ther. (2005) 3(4):467-487.
   PubMedGoogle Scholar
• MUNAYYER HK, MANN PA, CHAU AS et al.: Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob. Agents Chemother. (2004) 48(10):3690-3696.
   PubMed Web of Science ®Google Scholar
• KEATING GM: Posaconazole. Drugs (2005) 65(11):1553-1567; discussion 1568-1559.
   PubMed Web of Science ®Google Scholar
• WEXLER D, COURTNEY R, RICHARDS W et al.: Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J. Pharm. Sci. (2004) 21(5):645-653.
   PubMed Web of Science ®Google Scholar
• HOF H: A new, broad-spectrum azole antifungal: posaconazole – mechanisms of action and resistance, spectrum of activity. Mycoses (2006) 49(Suppl. 1):2-6.
   PubMed Web of Science ®Google Scholar
• LUPETTI A, DANESI R, CAMPA M, DEL TACCA M, KELLY S: Molecular basis of resistance to azole antifungals. Trends Mol. Med. (2002) 8(2):76-81.
   PubMed Web of Science ®Google Scholar
• HEIMARK L, SHIPKOVA P, GREENE J et al.: Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J. Mass Spectrom. (2002) 37(3):265-269.
   PubMed Web of Science ®Google Scholar
• XIAO L, MADISON V, CHAU AS et al.: Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. (2004) 48(2):568-574.
   PubMed Web of Science ®Google Scholar
• AKINS RA: An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol. (2005) 43(4):285-318.
   PubMed Web of Science ®Google Scholar
• CHAU AS, MENDRICK CA, SABATELLI FJ, LOEBENBERG D, MCNICHOLAS PM: Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob. Agents Chemother. (2004) 48(6):2124-2131.
   PubMed Web of Science ®Google Scholar
• LI X, BROWN N, CHAU AS et al.: Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J. Antimicrob. Chemother. (2004) 53(1):74-80.
   PubMed Web of Science ®Google Scholar
• COURTNEY R, PAI S, LAUGHLIN M, LIM J, BATRA V: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. (2003) 47(9):2788-2795.
   PubMed Web of Science ®Google Scholar
• EZZET F, WEXLER D, COURTNEY R et al.: Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. (2005) 44(2):211-220.
   PubMed Web of Science ®Google Scholar
• COURTNEY R, WEXLER D, RADWANSKI E, LIM J, LAUGHLIN M: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. (2004) 57(2):218-222.
   PubMed Web of Science ®Google Scholar
• COURTNEY R, RADWANSKI E, LIM J, LAUGHLIN M: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. (2004) 48(3):804-808.
   PubMed Web of Science ®Google Scholar
• KRIETER P, FLANNERY B, MUSICK T et al.: Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. (2004) 48(9):3543-3551.
   PubMed Web of Science ®Google Scholar
• GHOSAL A, HAPANGAMA N, YUAN Y et al.: Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab. Dispos. (2004) 32(2):267-271.
   PubMed Web of Science ®Google Scholar
• COURTNEY R, SANSONE A, SMITH W et al.: Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. (2005) 45(2):185-192.
   PubMed Web of Science ®Google Scholar
• GUDLAUGSSON O, GILLESPIE S, LEE K et al.: Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. (2003) 37(9):1172-1177.
   PubMed Web of Science ®Google Scholar
• WEY SB, MORI M, PFALLER MA, WOOLSON RF, WENZEL RP: Risk factors for hospital-acquired candidemia. A matched case-control study. Arch. Intern. Med. (1989) 149(10):2349-2353.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, REX JH, LEE J et al.: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. (2003) 37(5):634-643.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, JONES RN, DOERN GV et al.: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J. Clin. Microbiol. (1998) 36(7):1886-1889.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, ESPINEL-INGROFF A, JONES RN: Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J. Clin. Microbiol. (2004) 42(10):4577-4580.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ et al.: In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob. Agents Chemother. (1998) 42(12):3242-3244.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN: In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2001) 45(10):2862-2864.
   PubMed Web of Science ®Google Scholar
• CACCIAPUOTI A, LOEBENBERG D, CORCORAN E et al.: In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. (2000) 44(8):2017-2022.
   PubMed Web of Science ®Google Scholar
• ZAOUTIS TE, FORAKER E, MCGOWAN KL et al.: Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children’s hospitals. Diagn. Microbiol. Infect. Dis. (2005) 52(4):295-298.
   PubMed Web of Science ®Google Scholar
• LAVERDIERE M, HOBAN D, RESTIERI C, HABEL F: In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. (2002) 50(1):119-123.
   PubMed Web of Science ®Google Scholar
• CARRILLO-MUNOZ AJ, QUINDOS G, RUESGA M et al.: Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J. Antimicrob. Chemother. (2005) 55(3):317-319.
   PubMed Web of Science ®Google Scholar
• CUENCA-ESTRELLA M, GOMEZ-LOPEZ A, MELLADO E et al.: Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. (2006) 50(3):917-921.
   PubMed Web of Science ®Google Scholar
• SABATELLI F, PATEL R, MANN PA et al.: In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. (2006) 50(6):2009-2015.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. (2003) 20(4):121-136.
   PubMedGoogle Scholar
• APERIS G, MYRIOUNIS N, SPANAKIS EK, MYLONAKIS E: Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin. Investig. Drugs (2006) 15(11):1319-1336.
   PubMed Web of Science ®Google Scholar
• DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN, PFALLER MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. (2003) 41(8):3623-3626.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. (2002) 347(6):408-415.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. (2002) 46(4):1032-1037.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36(10):2950-2956.
   PubMed Web of Science ®Google Scholar
• GUINEA J, PELAEZ T, ALCALA L, RUIZ-SERRANO MJ, BOUZA E: Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob. Agents Chemother. (2005) 49(8):3495-3497.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, HERNANDEZ S, BOCANEGRA R, NAJVAR LK: Antifungal therapy of murine Aspergillus terreus infection. Antimicrob. Agents Chemother. (2004) 48(10):3715-3719.
   PubMed Web of Science ®Google Scholar
• IMAI JK, SINGH G, CLEMONS KV, STEVENS DA: Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. (2004) 48(10):4063-4066.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK WR, MCATEE RK, FOTHERGILL AW et al.: Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. (2000) 44(3):780-782.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MORRISSEY G, DENNING DW: Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. (1997) 41(7):1504-1507.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL AH et al.: Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. (2001) 45(3):857-869.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, PETRAITIS V, PETRAITIENE R et al.: Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. (2003) 188(2):305-319.
   PubMed Web of Science ®Google Scholar
• PATERA AC, MENZEL F, JACKSON C et al.: Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob. Agents Chemother. (2004) 48(8):3154-3158.
   PubMed Web of Science ®Google Scholar
• NAJVAR LK, CACCIAPUOTI A, HERNANDEZ S et al.: Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob. Agents Chemother. (2004) 48(3):758-764.
   PubMed Web of Science ®Google Scholar
• PERFECT JR, COX GM, DODGE RK, SCHELL WA: In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (1996) 40(8):1910-1913.
   PubMed Web of Science ®Google Scholar
• CACCIAPUOTI A, HALPERN J, MENDRICK C et al.: Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother. (2006) 50(7):2587-2590.
   PubMed Web of Science ®Google Scholar
• RODEN MM, ZAOUTIS TE, BUCHANAN WL et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. (2005) 41(5):634-653.
   PubMed Web of Science ®Google Scholar
• DANNAOUI E, MELETIADIS J, MOUTON JW, MEIS JF, VERWEIJ PE: In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. (2003) 51(1):45-52.
   PubMed Web of Science ®Google Scholar
• SUN QN, FOTHERGILL AW, MCCARTHY DI, RINALDI MG, GRAYBILL JR: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. (2002) 46(5):1581-1582.
   PubMed Web of Science ®Google Scholar
• SUN QN, NAJVAR LK, BOCANEGRA R, LOEBENBERG D, GRAYBILL JR: In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. (2002) 46(7):2310-2312.
   PubMed Web of Science ®Google Scholar
• DANNAOUI E, MEIS JF, LOEBENBERG D, VERWEIJ PE: Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. (2003) 47(11):3647-3650.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, BOYKEN L et al.: Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. (2005) 43(5):2163-2167.
   PubMed Web of Science ®Google Scholar
• BARCHIESI F, SCHIMIZZI AM, CASELLI F et al.: Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J. Antimicrob. Chemother. (2001) 48(6):769-773.
   PubMed Web of Science ®Google Scholar
• MELETIADIS J, MEIS JF, MOUTON JW et al.: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. (2002) 46(1):62-68.
   PubMed Web of Science ®Google Scholar
• GILGADO F, SERENA C, CANO J, GENE J, GUARRO J: Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob. Agents Chemother. (2006) 50(12):4211-4213.
   PubMed Web of Science ®Google Scholar
• SUGAR AM, LIU XP: In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. (1996) 40(5):1314-1316.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, TIJERINA R, NAJVAR LK et al.: In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob. Agents Chemother. (2002) 46(5):1352-1356.
   PubMed Web of Science ®Google Scholar
• LUTZ JE, CLEMONS KV, ARISTIZABAL BH, STEVENS DA: Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. (1997) 41(7):1558-1561.
   PubMed Web of Science ®Google Scholar
• CONNOLLY P, WHEAT J, SCHNIZLEIN-BICK C et al.: Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. (1999) 43(2):322-328.
   PubMed Web of Science ®Google Scholar
• CONNOLLY P, WHEAT LJ, SCHNIZLEIN-BICK C et al.: Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob. Agents Chemother. (2000) 44(10):2604-2608.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, TIJERINA R, NAJVAR LK et al.: Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob. Agents Chemother. (2003) 47(4):1436-1438.
   PubMed Web of Science ®Google Scholar
• SIMITSOPOULOU M, GIL-LAMAIGNERE C, AVRAMIDIS N et al.: Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob. Agents Chemother. (2004) 48(10):3801-3805.
   PubMed Web of Science ®Google Scholar
• LOZANO-CHIU M, ARIKAN S, PAETZNICK VL et al.: Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. (1999) 43(3):589-591.
   PubMed Web of Science ®Google Scholar
• VAZQUEZ JA, SKIEST DJ, NIETO L et al.: A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. (2006) 42(8):1179-1186.
   PubMed Web of Science ®Google Scholar
• NIETO L NR, PITISUTTIHUM P et al.: Posaconazole equivalent to fluconazole in the treatment of oropharyngeal candidiasis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada 2000.
   Google Scholar
• WALSH TJ, RAAD I, PATTERSON TF et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. (2007) 44(1):2-12.
   PubMed Web of Science ®Google Scholar
• VAN BURIK JA, HARE RS, SOLOMON HF, CORRADO ML, KONTOYIANNIS DP: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. (2006) 42(7):e61-e65.
   PubMed Web of Science ®Google Scholar
• GREENBERG RN, MULLANE K, VAN BURIK JA et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. (2006) 50(1):126-133.
   PubMed Web of Science ®Google Scholar
• PAGE RL, SCHWIESOW J, HILTS A: Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy (2007) 27(2):290-298.
   PubMed Web of Science ®Google Scholar
• TOBON AM, ARANGO M, FERNANDEZ D, RESTREPO A: Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. (2003) 36(11):1488-1491.
   PubMed Web of Science ®Google Scholar
• PITISUTTITHUM P, NEGRONI R, GRAYBILL JR et al.: Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. (2005) 56(4):745-755.
   PubMed Web of Science ®Google Scholar
• ANSTEAD GM, CORCORAN G, LEWIS J, BERG D, GRAYBILL JR: Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis. (2005) 40(12):1770-1776.
   PubMed Web of Science ®Google Scholar
• RAAD II, HACHEM RY, HERBRECHT R et al.: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. (2006) 42(10):1398-1403.
   PubMed Web of Science ®Google Scholar
• RESTREPO A, TOBON A, CLARK B et al.: Salvage treatment of histoplasmosis with posaconazole. J. Infect. (2006) 54(4):319-327.
   PubMed Web of Science ®Google Scholar
• SEGAL BH, BARNHART LA, ANDERSON VL et al.: Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. (2005) 40(11):1684-1688.
   PubMed Web of Science ®Google Scholar
• ULLMANN AJ, LIPTON JH, VESOLE DH et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. (2007) 356(4):335-347.
   PubMed Web of Science ®Google Scholar
• CORNELY OA, MAERTENS J, WINSTON DJ et al.: Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. (2007) 356(4):348-359.
   PubMed Web of Science ®Google Scholar
• RAAD II, GRAYBILL JR, BUSTAMANTE AB et al.: Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. (2006) 42(12):1726-1734.
   PubMed Web of Science ®Google Scholar
• GOPAL SANSONE-PARSONS A: Pharmacokinetics of posaconazole in healthy volunteers: pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five Phase I studies. American Society of Health-System Pharmacists. Anaheim (CA) USA (3 – 7 December 2006).
   Google Scholar